concentrations of acetaminophen showed that drug metabolism was compromised in CCHH but not in MMHH. Our results suggest that the MMHH system represents a convenient and robust in vitro experimental system for the evaluation of drug metabolism.
Introduction
Successful cryopreservation of human hepatocytes is a major reason for the routine application of this experimental system for preclinical assessment of human-specific drug properties including metabolic fate, drug-drug interactions, and drug toxicity (Li 2007; Godoy, Hewitt et al. 2013; Jones, Srivastava et al. 2017; Wood, Houston et al. 2017) . As the functional performance of the cryopreserved human hepatocytes can be significantly compromised by cellular damage, use of cryopreserved human hepatocytes requires the practitioners to have extensive experience with handling procedures including thawing, centrifugation, resuspension, microscopic quantification of cell viability, adjustment of cell concentration, and the ultimate delivery of the cells into experimental vessels for experimentation.
Furthermore, the use of cryopreserved hepatocytes requires the liquid nitrogen cryogenic freezers for storage which may not be readily available in laboratories where in vitro drug metabolism studies are routinely performed.
Before the development of cryopreserved hepatocyte technologies, hepatic subcellular fractions such as human liver microsomes (HLM) and post-mitochondrial supernatants (S9 or S10), were used exclusively in drug metabolism studies (Iwatsubo, Suzuki et al. 1997; Gombar, Silver et al. 2003) . These subcellular systems, especially HLM, remain to be practical and useful experimental systems in pharmaceutical industrial laboratories including screening of new chemical entities for metabolic stability (Halladay, Wong et al. 2007; Choi, Furimsky et al. 2015) , estimation of in vivo hepatic clearance (Obach 2011; Chen, Prieto Garcia et al. 2017) , evaluation of P450-related drug properties (Dinger, Meyer et al. 2014) , and UGT-mediated drug metabolism (Walsky, Bauman et al. 2012; Joo, Lee et al. 2014) . As compared to cryopreserved hepatocytes, the use of subcellular fractions requires relatively simple application procedures, and are relative robust and are not readily subjected to functional damages due to handling. A major drawback of the use of subcellular fractions is the incompleteness of the drug
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This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on January 23, 2018 as DOI: 10.1124 at ASPET Journals on January 29, 2018 dmd.aspetjournals.org Downloaded from metabolizing enzyme pathways, thus the data obtained may not allow an accurate assessment of in vivo hepatic metabolic fates. In contrast, cryopreserved hepatocytes contain complete, undisrupted drug metabolizing enzymes and cofactors, and are considered the "gold standard" for the evaluation of in vitro human drug metabolism (Fabre, Combalbert et al. 1990; Ulrich, Bacon et al. 1995; Hewitt, Lechon et al. 2007) . For this reason, in spite of the relatively more complicated experimental procedures, cryopreserved human hepatocytes have been applied in studies routinely performed with subcellular fractions including hepatic clearance (Di, Atkinson et al. 2013; Peng, Doshi et al. 2016 ) and P450 inhibition Li and Doshi 2011; Kazmi, Barbara et al. 2015) in order to obtain data that are more likely to reflect in vivo events.
It would be desirable to have an experimental system that combines the completeness of the drug metabolizing enzyme pathways in hepatocytes, and the robustness and simplicity of the application procedures of subcellular fractions. Towards this goal we have developed a novel experimental system, the MetMax™ human hepatocytes (MMHH). MMHH are permeabilized cryopreserved human hepatocytes supplemented with key drug metabolizing enzyme cofactors. Similar to subcellular fractions such as human liver microsomes, MMHH can be stored at -80 o C in contrast to the conventional cryopreserved human hepatocytes (CCHH) which require liquid nitrogen storage.
Furthermore, similar to subcellular fractions, MMHH can be used directly after thawing without centrifugation and microscopic evaluation of viability and cell concentration as required for CCHH.
We report here a comparison of MMHH and CCHH in phase 1 oxidation and phase 2 conjugation drug metabolizing enzyme (DME) activities as part of our ongoing research program to evaluate of the applicability of this novel experimental system to study drug metabolism.
Materials and Methods
Chemicals. Dextrorphan tartrate, diclofenac sodium salt, 4-hydroxydiclofenac, S-mephenytoin, 4-hydroxyquinoline, paclitaxel, and testosterone were purchased from Cayman Chemical (Ann Arbor, MI). (30, 60, 90 120 and 240 minutes) . At the end of each incubation, 100 L of acetonitrile was added into each well to terminate metabolism. The plates after termination were stored in a -80 o C freezer for later LC/MS-MS quantification of metabolite formation. All DME activity studies were performed at a final cell density of 1 x 10 6 cells/mL except for the evaluation of cell density versus metabolite formation where CCHH and MMHH were firstly prepared at cell concentrations of 4 x 10 6 cells per mL, followed by dilution to 2 x 10 6 , 1 x 10 6 , and 0.5 x 10 6 per mL before addition to the substrate plates, thereby yielding final concentrations of 2 x 10 6 , 1 x 10 6 , 0.5 x 10 6 and 0.25 x 10 6 mL.
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This article has not been copyedited and formatted. The final version may differ from this version. Table 2 ). An Agilent Zorbax Eclipse Plus C18 column (4.6 x 75 mm i.d., 3.5 μm; Agilent Technologies, Santa Clara, CA) at a flow rate of 1 mL/min was used for the chromatography separation. The mobile phase consisted of 0.1 % formic acid in acetonitrile (A) and 0.1 % formic acid in water (B). The gradient for the positive ion mode operation was programed as: 0 to 2.5 min, increase B from 5 to 95%; 2.5 to 3.5 min, 95% B; 3.5 to 3.6min, decrease B to 5%; run-time 5 min. The gradient program for the negative ion mode was: 0 to 3 min, increase B from 5 to 95%; 3 to 4 min, 95% B; 4 to 4.2 min, decrease B to 5%; run-time 6 min. Data acquisition and data procession were performed with the software Analyst 1.6.2 (AB SCIEX, Framingham, MA).
Data Analysis. Data are presented as mean and standard deviation of triplicate incubations derived using the Microsoft Excel 6.0 software. Statistical analysis was performed using student's t-test with the Microsoft Excel 6.0 software, with the probability of p<0.05 to be considered statistically significant.
Specific activity (pmol/min/million hepatocytes) of each drug metabolizing enzyme pathway was determined by dividing the total metabolite formed by the incubation time and normalized to cell concentration.
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Results
Cell morphology. When placed into a cell culture plate, the hepatocytes from MMHH appeared as intact cells which rapidly settled on the bottom of the wells. Phase contrast microphotography showed that MMHH were intact (not lysed) cells with distinct cell membranes (Fig. 1) , similar to CCHH (not shown).
Trypan blue exclusion evaluation, however, showed that 100% of the cells would include the dye (data not shown), demonstrating that their plasma membranes were permeabilized.
Cell concentration versus metabolite formation: MMHH were incubated for 30 min with various P450
isoform-selective substrates at 0.25, 0.5, 1.0 and 2.0 x 10 6 cells/mL. Metabolite formation was found to increase with cell concentration for all the substrates evaluated (Fig. 2) . From the results, 1.0 x 10 6 cells/mL was chosen as the cell concentration for subsequent studies.
Incubation duration versus metabolite formation: MMHH and CCHH were incubated with various pathway-selective substrates for 30, 60, 120 and 240 minutes. In general, similar relationships between metabolite formation and incubation duration were observed for the two hepatocyte systems, with linear or curve-linear time course (Fig. 3) .
Secondary metabolite formation:
1. 7-Ethoxycoumarin metabolism: MMHH and CCHH were incubated with 7-ethoxycoumarin.
7-ethoxycoumarin is firstly oxidation to 7-hydroxycoumarin which in turn is subjected to metabolism by UDPGT and SULT to 7-hydroxycoumarin glucuronide and 7-hydroxycoumarin sulfate, respectively. Similar metabolite profiles were observed for MMHH and CCHH, with 7-hydroxycoumarin found to be extensively conjugated to the glucuronide and sulfate conjugates (Fig. 4) .
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Significant reduction of acetaminophen metabolism was observed at 200 mM in CCHH which was contributed to the cytotoxic effects at this drug concentration. No apparent reduction in metabolite formation was observed in MMHH at 200 mM of acetaminophen .
Cofactor-mediated selection of metabolic pathways in MMHH:
MMHH was prepared without cofactors and then incubated with coumarin with the following cofactor compositions: 1. NADPH (without UDPGA nor PAPS); 2. NADPH plus UDPGA (without PAPS); and 3. NADPH plus PAPS (without UDPGA).
7-hydroxycoumarin was formed under all three cofactor compositions. 7-hydroxy and 7-glucuronide but not the 7-sulfate metabolites but were observed under condition 2. 7-hydroxylation and 7-sulfate but not the 7-glucuronide metabolites were observed under condition 3. (Fig. 6) 
Activity comparison between MMHH and CCHH:
A comparison of the rates of metabolism of the various drug metabolism enzyme-selective substrates in MMHH and is shown in Fig. 7 with MMHH activities expressed as percentages of that for CCHH (Fig. 7A ) and with MMHH activities plotted versus CCHH (Fig.   7B ). Numerical data for drug metabolizing enzyme activities for MMHH and CCHH are presented in the
This article has not been copyedited and formatted. The final version may differ from this version. supplementary materials section (Supplement Table 3 ). The results demonstrate that MMHH were active in all the enzyme pathways evaluated, with activities in general similar to that observed in CCHH.
Discussion
The major focus of our laboratory is the development and application of in vitro human-based experimental systems to allow accurate assessment of human drug properties. Our laboratory was one
of the first to demonstrate successful cryopreservation of human hepatocytes (Loretz, Li et al. 1989; Li 2015 ) and more recently, human enterocytes (Ho, Ring et al. 2017) , to retain viability and drug metabolism activities. We report here the characterization of a novel experimental system, namely, the MMHH experimental system -permeabilized, cofactor-supplemented cryopreserved human hepatocytes. MMHH was developed in our laboratory to be an in vitro tool for drug metabolism studies with the desirable properties of both hepatocytes and subcellular fractions. As permeabilized, not lysed, cells, the MMHH retain cellular integrity and subcellular structures and thereby contain complete enzyme pathways akin to CCHH. As the drug metabolizing enzyme activities of MMHH are driven by the cofactors and therefore not affected by viability, MMHH, like subcellular fractions, are not subjected to handling damages which can drastically affect the functions of CCHH. The presence of all the cellular organelles and the associated drug metabolizing enzymes are the reasons that CCHH are considered the "gold standard" in vitro drug metabolism system. These are also the attributes of MMHH, but not subcellular fractions which contain only a portion of the organelles and therefore lacking the drug metabolizing enzymes associated with the missing organelles (Table 3) .
A comparison of MMHH and CCHH in the activities of key drug metabolizing enzyme pathways showed no apparent deficiencies in these activities in MMHH. Both experimental systems were competent in phase 1 oxidation and phase 2 conjugation, including sequential events with oxidation followed by
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Activities observed in MMHH as percent of that in CCHH based on the rate of metabolite formation after an incubation duration of 30 minutes are: UGT (271%), GST (234%), SULT (204%), CYP1A2 (180%), CYP2A6 (177%), CYP2B6 (146%), CYP2C8 (131%), CYP2C9 (187%), CYP2E1 (132%), CYP3A4 (midazolam 1'hydroxylation: (151%); testosterone 6b-hydroxylation: (159%); CYP2J2 (100%); ECOD (179%); FMO (169%); NAT1 (134%); CYP2C19 (57%); CYP2D6 (86%); MAO (89%); AO (34%); CES2 (27%); acetaminophen glucuronidation (80%); and acetaminophen sulfation (43%).
Our results therefore show that MMHH are active in all drug metabolizing enzyme pathways evaluated with activities comparable to that for CCHH, thereby suggesting that MMHH can be used for drug metabolism studies that routinely employ CCHH. The advantages MMHH over CCHH include storage at -80 o C instead of liquid nitrogen to retain viability and functions, used directly after thawing without a need for centrifugation cell recovery and microscopy examination of cell viability and cell concentration determination. We have estimated that the time required from thawing to incubation for drug metabolism evaluation was approximately 7 -10 minutes for MMHH versus 30.5 -45 minutes for CCHH (Table 4) . Further, unlike CCHH in which cofactor compositions cannot be readily controlled, specific metabolic pathway can be evaluated with MMHH based on the composition of the added cofactor mixtures. Selection of metabolic pathways based on cofactor compositions in MMHH is demonstrated with coumarin metabolism where the use of UDPGA in the absence of PAPS led to formation of coumarin 7-glucuronide with no sulfate conjugate and vice versa.
This article has not been copyedited and formatted. The final version may differ from this version. Our experimental findings suggest that MMHH may represent a convenient hepatocyte-based experimental system that can be used for drug metabolism studies. Studies have been initiated in our laboratory in the applications of MMHH in the evaluation of metabolic stability and metabolite profiling, as well as reversible and mechanism-based drug metabolizing enzyme inhibition. It needs to be emphasized, however, that CCHH remain valuable and cannot be replaced with MMHH in the evaluation of a number of key drug properties. These include uptake and efflux transport (Shitara, Li et al. 2003; Bi, Scialis et al. 2017; Izumi, Nozaki et al. 2017; Zhang, Jackson et al. 2017 ) which require intact plasma membranes, enzyme induction (Fahmi, Boldt et al. 2008; Zhou, Andersson et al. 2011; Jones, Rollison et al. 2017 ) which requires RNA and protein synthesis, and in vitro hepatotoxicity (Zhang, Doshi et al. 2016; Andersson 2017; Proctor, Foster et al. 2017 ) which requires intact, viable hepatocytes. We believe that MMHH should be complementary to current in vitro systems for the evaluation of human drug metabolism.
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